TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) Q3 2022 Earnings Conference Call November 14, 2022 5:00 PM ET
Company Participants
Corey Davis - LifeSci Advisors
Glenn Mattes - President, CEO & Director
Dale Christensen - Head, Clinical Development
Kirk Coleman - CFO, Treasurer & Secretary
Robert Williams - Technology Inventor & Special Advisor
Conference Call Participants
Jonathan Aschoff - ROTH Capital Partners
Vernon Bernardino - H.C. Wainwright & Co.
Michael Okunewitch - Maxim Group
Operator
Greetings, and welcome to the TFF Pharmaceuticals, Inc. Third Quarter 2022 Earnings Conference Call. [Operator Instructions].
It is now my pleasure to introduce Corey Davis. Thank you, and you may proceed.
Corey Davis
Thank you, operator. Hello, everyone, and welcome to TFF Pharmaceuticals' Third Quarter Financial and Business Results Conference Call. With me on the line today is Glenn Mattes, President and CEO of TFF; Kirk Coleman, Chief Financial Officer; Dr. Dale Christensen, TFF's Head of Preclinical and Clinical Development; Dr. Bill Williams of the University of Texas at Austin; and Chris Cano, TFS's Chief Operating Officer. .
A press release announcing our third quarter results is available on the recently updated TFF Pharmaceuticals website, and we hope you all have an opportunity to visit the site soon. Please take a moment to read the disclaimer about forward-looking statements in the press release.
The earnings release and this teleconference both include forward-looking statements, and these forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially from the statements made. Factors that could cause actual results to differ are described in the disclaimer and in our filings with the U.S. Securities and Exchange Commission, including the Risk Factors section of our 2021 annual report on Form 10-K filed with the SEC.
And now it's my pleasure to turn the call over to Mr. Glenn Mattes. Go ahead, Glenn.
Glenn Mattes
Good afternoon. Thank you for joining us today to review TFF third quarter operations and recent highlights. During this call, I'll provide an update on our overall progress and then ask our Chief Financial Officer, Kirk Coleman, to review our third quarter financials. Kirk and I will provide the formal commentary and then open up the call for questions. Please note that we are joined by Dr. Bill Williams, Dr. Dale Christensen and Chris Cano, who are also available to help answer questions. .
On our last quarter's conference call, we spent a considerable amount of time highlighting the unique attributes of thin film freezing and why we believe this technology can be broadly applied our internal portfolio partnership opportunities. This quarter, I would like to discuss how we're actively applying thin film freezing to real-world clinical practice that, in my view, will create significant value for patients, our internal pipeline partner programs and for our shareholders.